Combining inhaled hyperoxia and olaparib for treating lung metastases in uveal and cutaneous melanoma
Year: 2026
Type: article
Abstract: Uveal melanoma is highly metastatic, particularly to the liver and lungs, and is frequently associated with loss on chromosome 3 and a gain on chromosome 8. This alteration promotes sustained tumor hypoxia, making this cancer type a strong candidate for reoxygenation strategies aimed at limiting tumor adaptation to hypoxia. Here, we investigated the therapeutic potential of supplemental oxygen, alone or in combination with the PARP inhibitor olaparib which has also been shown to impair tumor adaptation to hypoxia and the would attenuates hyperoxia-induced inflammatory burst, in uveal melanoma cell lines. Non-tumoural lung epithelial cells served as control. Exposure to supplemental oxygen increased oxidative stress and impaired uveal melanoma cell viability, proliferation, and migration, while control cells were minimally affected. Co-treatment with olaparib effectively modulates the hyperoxia-induced inflammatory response. Notably, both hyperoxia and the combination treatment triggered pyroptosis, an immunogenic form of cell death. In vivo, a partial model of metastatic cutaneous melanoma exposed to inhaled hyperoxia showed a significant reduction in lung metastatic burden. These findings support the use of reoxygenation combined with PARP1 inhibitors as a promising strategy to enhance tumor stress responses and promote immunogenic cell death in metastatic uveal melanoma, with an emphasis on the modulation of inflammatory signaling.
Source: Cell Death and Disease
Institutions: Consejo Superior de Investigaciones Científicas, Instituto de Parasitología y Biomedicina "López - Neyra", Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Universidad de Granada, Biomedical Research Networking Center on Neurodegenerative Diseases, Wellcome Sanger Institute
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W7234050121
